Aclaris Therapeutics, Inc. (ACRS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-28

Key Insights

Aclaris announced positive Phase 1a results for ATI-052, a bispecific antibody targeting anti-TSLP/IL-4Rα, demonstrating clinical progress in its pipeline and de-risking early-stage development.
The company selected lichen planus as the lead indication for ATI-2138 (selective ITK/JAK3 inhibitor), indicating advancement in clinical development strategy and potential market opportunity identification for this asset.
This is a Regulation FD disclosure filed via 8-K, meaning the information is being disclosed to the market through a conference call presentation and press release, which is typical for clinical trial results from biotech companies.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-11

The company raised $20 million through a public stock offering, indicating potential for growth and expansion.
The shares were purchased by several major institutional investors, suggesting strong investor confidence in the company's prospects.
The filing does not provide any additional details about the company's financial performance or strategic plans, limiting the insight that can be gleaned from this 8-K.

Filed: 2026-03-10

Aclaris Therapeutics raised $39.8 million through a stock offering, which could provide additional funding to support its ongoing operations and development programs.
The shares were purchased by institutional investors, including Deep Track Capital, indicating institutional investor interest in the company.
The filing discloses the details of the stock offering, providing transparency to investors about the company's capital-raising activities.

Filed: 2026-01-12

Aclaris Therapeutics has updated its corporate overview presentation, which could provide investors with new information on the company's business and strategic initiatives.
The filing does not indicate any material changes to Aclaris's financial condition, operations, or leadership, suggesting this update is likely a routine disclosure.
Investors should review the updated presentation on the company's website for any potential insights into Aclaris's pipeline, market opportunities, or other key developments.

Other reports for Aclaris Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.